A Study Assessing Efficacy of HMG-CoA Reductase Inhibitor/Cholesterol Ointment for Porokeratosis

A Multicenter, Double-blind, Randomized Exploratory Study Assessing Efficacy of HMG-CoA Reductase Inhibitor/Cholesterol Ointment for Porokeratosis - HMG-CoA/Chol trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031190203

Enrollment

Registered

2020-02-06

Start date

2020-03-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Porokeratosis porokeratosis

Interventions

Apply 1% atorvastatin/2% Cholesterol externally on the lesions every day for 24 weeks

D000069059

Atorvastatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Clinically or histopathologically diagnosed with porokeratosis More than two lesions or have a lesion of at lease 10cm in diameter Obtained consent

Exclusion criteria

Exclusion criteria: Patients with contraindications to atorvastatin use

Design outcomes

Primary

Measure	Time frame
Improvement rate of hyperkeratosis	—

Secondary

Measure	Time frame
Time course of hyperkeratosis The area of the lesion Evaluation by the subjects The change of the lesion using dermoscope The pathological change before and after intervention	—

Contacts

Public ContactSatoru Shinkuma

Niigata University

shinkuma@naramed-u.ac.jp+81-25-227-2282

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026